In an editorial accompanying the studies, Jerry Avorn and Aaron Kesselheim of Harvard Medical School and Brigham and Women's Hospital, Boston, questioned whether "improper" marketing may have contributed to the off-label use of NovoSeven.
"It appears that this is a class effect, " New England Journal of Medicine Editor Jeffrey Drazen writes in a blunt editorial accompanying the three studies.
While the Colorado researcher didn't know if the study participants were smokers or non-smokers, the CDC's editorial points out that the new study adds to research from eight other studies, which also saw a drop in heart attack related hospitalizations after smoke-free laws are enforced.